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Abstract
Background: In a recent case–control study, long-term use of calcium channel blocking drugs was associated with
a greater-than-twofold increased breast cancer risk. If prospectively collected data confirm that calcium channel
blocker use increases breast cancer risk, this would have major implications for hypertension treatment. The
objective of this study was to determine whether women using calcium channel blockers for 10 years or more
were at increased risk of developing breast cancer compared with women not using calcium channel blockers.
Methods: The Sister Study is a prospective volunteer cohort study of women from the USA and Puerto Rico
designed to evaluate environmental and genetic risk factors for breast cancer. Beginning in 2003, women between
the ages of 35 and 74 were recruited. They were eligible to participate if they had a sister with breast cancer but
had not been diagnosed with breast cancer themselves. In total, 50,884 women enrolled in the cohort between
2003 and 2009; 50,757 women with relevant baseline data and available follow-up data are included in this study.
The exposure of interest is current use of calcium channel blocking drugs and the reported duration of use at entry
into the cohort. Secondary exposures of interest were the duration and frequency of use for all other subclasses of
antihypertensive drugs. Our main outcome is a self-reported diagnosis of breast cancer during the study follow-up
period. With patient permission, self-reported diagnoses were confirmed using medical records.
Results: Results showed 15,817 participants were currently using an antihypertensive drug, and 3316 women were
currently using a calcium channel blocker at study baseline; 1965 women reported a breast cancer diagnosis during
study follow-up. Using Cox proportional hazards modeling, we found no increased risk of breast cancer among
women who had been using calcium channel blockers for 10 years or more compared with never users of calcium
channel blockers (HR 0.88, 95 % CI 0.58–1.33).
Conclusions: We saw no evidence of increased risk of breast cancer from 10 years or more of current calcium
channel blocker use. Our results do not support avoiding calcium channel blocking drugs in order to reduce breast
cancer risk.
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Background
Antihypertensive drugs constitute the most commonly
prescribed drug class in the USA. In 2010, Americans
filled 678.2 million antihypertensive drug prescriptions
[1, 2], and after starting, many individuals continue
taking the drug for the rest of their lives [2]. The as-
sociation between antihypertensives and breast cancer
risk has been evaluated in a limited number of studies
with mixed results.
A recent case–control study of women aged 55–74 re-
ported a twofold increased risk of breast cancer for
women who were current calcium channel blocker users
with at least 10 years of use [1]. This increased risk was
observed relative to women who had never used antihy-
pertensive drugs, and relative to women using another
type of antihypertensive for 10 years or more. They also
reported a higher risk increase for breast cancer for
women with current use of the nondihydropyridine sub-
class of calcium channel blockers compared with those
using dihydropyridines [1]. Several other case–control
studies have also reported increased breast cancer risk in
women who used calcium channel blockers [1, 3–5] or
with recent use (past 2 years) of immediate-release
(short-acting) calcium channel blockers [3] However,
case–control studies are limited in their ability to establish
causal risk associations; collecting exposure information
after disease diagnosis may lead to recall bias. Prospective
studies that assess exposure before disease diagnoses
occur are effective at minimizing biases related to differen-
tial exposure recall or possible medication changes follow-
ing breast cancer diagnosis and treatment. Prospective
studies may also provide a more accurate picture of expo-
sures during the at-risk period. A number of prospective
cohort studies have reported no association between
breast cancer and antihypertensive use in general or by
drug subclass [6–13]. However, uncertainty about calcium
channel blocker use and breast cancer risk remains; many
of these prospective studies have been limited by small
numbers of breast cancer cases, failure to examine drug
subclasses, or short durations of antihypertensive use.
Contemporary prospective cohort studies with many
long-term calcium channel blocker users are needed to
determine whether breast cancer risk is associated with
long-term use of these drugs. Although two recent cohort
studies with large sample sizes did not detect increased
risk of breast cancer among users of calcium channel
blockers [12, 13], studies of the general population might
not accurately capture elevated risks that may be amplified
in women with family histories of breast cancer through
interaction with other risk factors [14].
The Sister Study is a prospective cohort study of
50,884 women who had a sister with breast cancer and
thus are at increased risk of developing breast cancer
themselves. This study was designed specifically to capture
possible interactions between environmental and lifestyle
risk factors such as antihypertensive drug use, and the
genetic risk factors underlying familial breast cancer risk.
These data were collected in a time period when long-
term antihypertensive use was increasingly common
among women aged 50 and older, and therefore provide a
unique opportunity to evaluate the effect of long-term
calcium channel blocker use on breast cancer risk in
a higher-risk population of women.
Methods
Study population
The Sister Study is a volunteer cohort of women recruited
through media and community outreach across the USA
and Puerto Rico. Women were eligible to participate if
they had a sister with breast cancer and had never been
diagnosed with breast cancer themselves. Between 2003
and 2009, the cohort enrolled 50,884 women and partici-
pants completed in-person physical examinations and
baseline telephone interviews detailing medical, lifestyle,
dietary, and reproductive history. Participants are followed
for incident breast cancer diagnoses with annual health
updates supplemented with detailed biennial and triennial
questionnaires with follow-up response rates ≥94 %
[15, 16]. The study was approved by the Institutional Re-
view Board of the National Institute of Environmental
Health Sciences, NIH and the Copernicus Group Institu-
tional Review Board. Inclusion in this analysis is covered
by the informed consent form all included cohort partici-
pants agreed to and signed.
Sister Study participants are surveyed for development
of breast cancer annually, and are asked to report a new
breast cancer diagnosis between follow-ups. Reported
cases are confirmed with medical record retrieval. Self-
reports and medical records were also used to compile
and confirm information on tumor histology and hor-
mone receptor status. At the time of analysis (Data Re-
lease 2.0), approximately 91 % of women with breast
cancer consented to retrieval of their medical records. All
women who reported a breast cancer diagnosis had an op-
portunity to disavow their report; women who disavowed
their initial report of a breast cancer diagnosis (N = 3) are
not included as cases in this analysis. Of the 77 % of cases
(N = 1638) who had records available at the time of ana-
lysis, there was close agreement between self-report and
the medical record for the diagnosis of breast cancer
(99.5 %), classification of an invasive cancer (98.5 %), and
ER+ status (99 %), providing a high degree of confidence
in the use of self-report for those women with missing
medical record data. All available breast cancer diagnoses
collected during or prior to the last completed follow-up
phase as of 26 April 2013 were included.
Information on use of calcium channel blocking drugs
or use of other classes of antihypertensive drugs was
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obtained from the baseline Sister Study questionnaire.
Women were asked a series of questions designed to
capture information on all current and past medications
for all reported medical conditions. Information on
medication use collected in the survey included: the pa-
tient’s medical conditions; the name of each drug taken
for the reported medical conditions; how frequently each
drug was taken per week; and the first and last ages at
which the drug was taken. They were also asked to re-
port any additional medications taken that were not as-
sociated with the medical conditions they reported. To
minimize reporting errors, women were asked to have
their current medications on hand during the interview.
They were provided booklets with the names of com-
monly used medications for various conditions such as
hypertension prior to the interview to promote accurate
reporting of current medications and medications used
in the past. Each reported medication was coded by
product and class using the Slone Drug Dictionary
(Boston University, Boston, MA, USA). Products that con-
tained more than one active ingredient were assigned
multiple class codes.
We examined the effect of duration and class of anti-
hypertensive drug use on breast cancer risk. We in-
cluded use of antihypertensive drugs for all disease
indications and reported use without a specific indica-
tion listed. Covariates were obtained from the baseline
Sister Study questionnaires or measured during exam-
iner at-home visits; these included age, race/ethnicity,
underlying medical conditions and medical history, fam-
ily medical history, history of benign breast conditions,
smoking status, alcohol consumption habits, level of re-
ported physical activity, body mass index (BMI) from
examiner-measured height and weight, age at menarche,
menopausal status, hormonal exposures including hor-
mone replacement therapy and oral contraceptives, se-
lected dietary factors, and history of pregnancy and
breastfeeding. Baseline menopause status was deter-
mined by a women’s self-reported age at last menstrual
period (LMP); a women was considered postmenopausal
if 12 months or more had passed since her LMP at base-
line, or if her last LMP was determined to have occurred
pre baseline based on subsequent reports during study
follow-up. Women with hysterectomy or uterine surger-
ies were considered postmenopausal when they reached
the age of 56.
Statistical methods
We characterized use of calcium channel blockers and
other antihypertensive drugs in the cohort using stand-
ard contingency table methods with chi-square tests.
Univariate and multivariate logistic regression analyses
were used to identify potential covariates associated with
different levels of current and lifetime antihypertensive
use across drug subclasses. All statistical analyses were
conducted using SAS 9.3 (Cary, NC, USA).
To determine the association between calcium channel
blocker use and breast cancer risk, we calculated hazard
ratios (HRs) for strata of lifetime use and incident breast
cancer using multivariate Cox proportional hazard re-
gression. Calcium channel blocker use was categorized
into five levels: (1) never used calcium channel blocker;
(2) former user of calcium channel blocker; (3) current
user with less than 5 years of use; (4) current user with
5–10 years of use; and (5) current user with 10 years or
more of use. The same stratifications were used for use
of any type of antihypertensive drug, as well as for the
following classes of antihypertensive drugs: beta-blockers,
angiotensin-converting enzyme (ACE) inhibitors, diuretics,
angiotensin receptor blockers, and miscellaneous drugs.
Calcium channel blockers were also stratified into dihydro-
pyridines (amlodipine, felodipine, nifedipine SR, isradipine,
nifedipine, nicardipine) and nondihydropyridines (verap-
amil, diltiazem, verapamil SR, diltiazem XR). Women who
switched from one antihypertensive drug subclass to an-
other subclass before the baseline survey were considered
former users for their previous drug subclass, current users
for their current subclass, and current users of antihyper-
tensives in general.
Attained age serves as the time scale for the Cox
proportional hazards regression models. Participants
enter the analysis with their age at study enrollment,
and accrue person-time until they either exit at the age of
breast cancer diagnosis for cases or the age at their last
completed health questionnaire. Participants who failed to
respond to their most recent eligible health update were
censored at the earliest date among death or the midpoint
of the interval between the last completed health update
and the end of the window of eligibility for responding to
their first missed health update. We ran crude unadjusted
Cox proportional hazards regression models as well as a
multivariable model with adjustment for the following var-
iables selected as a-priori potential confounders based on
existing literature: baseline-measured BMI, race/ethnicity,
smoking status, parity, menopause status, age at menar-
che, history of breast conditions, current drinking level,
hormone replacement therapy use, and statin use. We also
ran models excluding women who reported prophylactic
mastectomy at baseline (N = 234), or with adjustment for
prophylactic tamoxifen and reloxifene use, but these fac-
tors had no material effect on our risk estimates and were
excluded from the final model.
As an a-priori hypothesis, we examined risk associated
with long-term use of calcium channel blocking drugs,
and additionally examined use of antihypertensives in
general and use of other subclasses of antihypertensive
drugs. We focused on use of calcium channel blockers
that lasted for 10 years or more, because this is the
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length of usage that has recently been associated with
breast cancer risk. We also conducted analyses where
long-term use was defined less strictly as 5 years or
more of use to provide increased statistical power for
risk detection. We examined risk associated with long-
term calcium channel blocker use by breast tumor char-
acteristics including tumor invasiveness at diagnosis and
estrogen receptor status. To make our results as com-
parable as possible with previously conducted studies,
we conducted sensitivity analyses limiting our analytical
group to: women who were postmenopausal at study
entry; and women who were aged 55 or older at study
entry. Additionally, we conducted an active comparator
sensitivity analysis in which we limited our analytical
group to women who were current users of an antihy-
pertensive drug: for at least 5 years; and for at least
10 years. This analysis allows for direct comparison of
long-term calcium channel blocker users with women
who were long-term users of another class of antihyper-
tensive drug.
Results
After excluding women missing relevant baseline or
follow-up data or who were diagnosed with breast can-
cer before completion of enrollment activities, we had
an analytical cohort of 50,757 women for this study:
17,068 women (33.6 %) reported ever taking an antihy-
pertensive drug in their lifetime; and 15,817 (31.2 %)
were currently using an antihypertensive drug, 3316 of
whom were currently using a calcium channel blocker at
study baseline. The majority of current antihypertensive
users (90.1 %) were postmenopausal at baseline. Demo-
graphic characteristics of women who had and had not
taken calcium channel blockers are presented in Table 1.
On average, women who reported calcium channel
blocker use were older than nonusers, with a mean age
at study baseline of 60.2 years compared with a mean of
54.5 years among women who had never used calcium
channel blockers (p < 0.0001). A larger proportion of cal-
cium channel blocker users were black (21 %) compared
with never users (8 %, p < 0.0001). Calcium channel
blocker users had higher BMIs than nonusers (p < 0.0001)
and were more likely to have used hormone replacement
therapy (p < 0.0001), both of which are established risk fac-
tors for postmenopausal breast cancer. Demographics for
users of all classes of antihypertensive drugs compared
with nonusers were very similar to calcium channel
blocker use alone (Additional file 1: Table S1).
Of the 3844 women in the cohort who reported
current use of calcium channel blockers (Table 2), 820
had been using calcium channel blockers for 10 years
or more. Among users of calcium channel blockers,
women with longer durations of calcium channel
blocker use were more likely than short-term users to
be postmenopausal or to have ever used hormonal
replacement therapy, both of which increase breast can-
cer risk (Additional file 1: Table S2).
Table 1 Study demographic characteristics of never users and
ever users of calcium channel blocking drugs at study baseline






Age at baseline 54.5 (48.0–61.0) 60.2 (55.0–66.0) <0.0001
Age at menarche 12.7 (12.0–13.0) 12.4 (11.5–13.0) <0.0001
Race <0.0001
Non-Hispanic White 39,705 (85) 2748 (71)
Non-Hispanic Black 3655 (8) 797 (21)
Hispanic 2311 (5) 197 (5)
Other 1219 (3) 110 (3)
Missing 14 (<1) 0 (<1)
Body mass index <0.0001
<25 18,588 (40) 786 (20)
25.0–29.9 14,953 (32) 1166 (30)
30.0–34.9 7839 (17) 944 (25)
35.0+ 5508 (12) 956 (25)
Missing 16 (<1) 1 (<1)
Menopause status <0.0001
Pre menopause 14,254 (30) 461 (12)
Post menopause 32,332 (69) 3381 (88)
Missing 318 (1) 11 (<1)
Ever pregnant <0.0001
No 5947 (13) 407 (11)
Yes 40,935 (87) 3445 (89)




No 26,193 (56) 1532 (40)
Yes 20,561 (44) 2313 (60)




No 44,612 (95) 3613 (94)
Yes 2241 (5) 230 (6)
Don’t know/missing 51 (<1) 10 (<1)
Smoking status <0.0001
Never smoked 26,441 (56) 2045 (53)
Past smoker 16,604 (35) 1487 (39)
Current smoker 3845 (8) 318 (8)
Don’t know/missing 14 (1) 3 (<1)
Data presented as mean (interquartile range) of N (%)
aCalculated using chi-square tests and Student’s t tests as appropriate
bCancers other than breast cancer (excluding basal-cell carcinoma)
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A total of 1965 women reported a breast cancer diag-
nosis during study follow-up: 1372 cases of invasive
breast cancer, and 558 cases that were classified as in
situ, and 35 cases in which invasiveness of the tumor
was unknown. The mean follow-up time for participants
in the cohort was 5.3 years (SD 1.69). Of invasive can-
cers, 1027 were classified as invasive ductal carcinomas
and 130 were invasive lobular carcinomas. Of the 558
in-situ cases, 459 were characterized as ductal carcinoma
in situ (DCIS).
Calcium channel blocker use patterns and use of anti-
hypertensive drugs in general did not differ between
women who developed breast cancer during follow-up
and those who remained free of breast cancer (Table 2).
Of women who remained cancer free, 1.3 % had been
users of calcium channel blockers for 10 years; this same
percentage of women with long-term calcium channel
blocker use (1.3 %) was observed among women who
developed invasive breast cancer. There were no differ-
ences in the distribution of drug usage across cases and
noncases for any other subclass of antihypertensive drug
(Additional file 1: Table S3).
Cox proportional hazards regression showed no evi-
dence of increased breast cancer risk with long-term
calcium channel blocker use either in unadjusted
models (Additional file 1: Table S4) or with adjustment for
covariates (Fig. 1). Unadjusted models utilized 50,751
women with 1959 breast cancer events. Owing to missing
covariate or follow-up time data, adjusted models resulted
in an analytic cohort of 50,269 women, with 1933 breast
cancer events. There was no increased risk of breast
cancer for any duration of calcium channel blocker
use when compared with women who had never used
Table 2 Use of antihypertensive drugs by breast cancer status
Antihypertensive use Noncases Invasive In situ Invasiveness unknown p value
48,792 1372 558 35
All antihypertensive drugs
Never used 32,413 (66.4) 883 (64.3) 375 (67.2) 18 (51.4)
0.32
Former user 1204 (2.5) 33 (2.4) 13 (2.3) 1 (2.9)
Current user (<5 years) 7410 (15.2) 208 (15.1) 92 (16.5) 5 (14.3)
(5–10 years) 4033 (8.3) 128 (9.3) 40 (7.2) 5 (14.3)
(10+ years) 3732 (7.6) 120 (8.8) 38 (6.8) 6 (17.1)
Calcium channel blockers
Never used 45,089 (92.4) 1270 (92.6) 515 (92.3) 30 (85.7)
0.41
Former user 516 (1.1) 15 (1.1) 6 (1.1) 0 (0)
Current user (<5 years) 1804 (3.7) 44 (3.2) 21 (3.8) 1 (2.9)
(5–10 years) 771 (1.6) 25 (1.8) 11 (2.0) 2 (5.7)
(10+ years) 612 (1.3) 18 (1.3) 5 (0.9) 2 (5.7)
Data presented as N (%)
Distribution of the duration of use for any antihypertensive drug and for use of calcium channel blockers specifically. We calculated distribution of use for women
who remained breast cancer free as well as those who developed breast cancer during the study follow-up period
Fig. 1 Hazard ratios of incident breast cancer by strata of calcium
channel blocker use (a) and by strata of use of all antihypertensive
drugs (b). HRs were calculated using Cox proportional hazards
regression with age as the time scale and adjusted for race/ethnicity,
categorized BMI, parity, age at menarche, menopause status, statin
use, smoking status, hormone therapy use, and reported hours of
physical activity per week
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calcium channel blockers (Fig. 1). Being a current user of
calcium channel blockers for 10 years or more did not in-
crease risk of breast cancer development during follow-up
compared with women who had never used calcium chan-
nel blockers (HR 0.88, 95 % CI 0.59–1.33). There was no
increased risk observed when long-term use was less
strictly categorized as 5 years or more of calcium channel
blocker use compared with never users (HR 1.016, 95 %
CI 0.78–1.32). Further stratified analysis of dihydropyri-
dine calcium channel blockers and nondihydropyridine
calcium channel blockers failed to show increased risk for
either class (Additional file 1: Table S5). We also explored
antihypertensive use and breast cancer risk more gener-
ally, looking at use of any antihypertensive drug (Fig. 1)
and various subclasses (Additional file 1: Table S6), but
found no evidence of association.
We also explored whether antihypertensive use was
associated with postmenopausal breast cancers or with
specific tumor subtypes. Analyses restricted to postmen-
opausal women (N = 38,604), women aged over 55, or
stratification by ethnicity revealed no increased risk for
calcium channel blocker use (Additional file 1: Figure S1).
We also conducted analyses stratified by various tumor
subtypes. We saw no increased risk for ER+ or ER– tumors
only, nor when stratified by invasiveness status at diagnosis
(Additional file 1:Supplemental Figure S1). We saw no in-
creased risk for invasive ductal carcinoma (N = 1009 cases),
for invasive lobular carcinoma (N = 130 cases), or for ductal
carcinoma in situ (N = 459 cases), which were the most
common types of incident breast cancers reported during
follow-up (Table 3). When the analytical pool was limited
to current users of antihypertensive drugs with at least
5 years of use (N = 8057) or with at least 10 years of use
(N = 3879), no increased risk of breast cancer was observed
with calcium channel blocker use compared with users of
the other classes of antihypertensive drugs (Table 4).
Discussion
Antihypertensive treatment is on the rise in the USA,
with a number of different classes of therapeutic agents
available. Calcium channel blockers have become an in-
creasingly common modality of treatment over the past
few decades [17, 18]. In light of the increasing prevalence
of calcium channel blocker use, recent reports of its po-
tential association with breast cancer could, if substanti-
ated, raise serious questions on how to balance the
considerable benefits of this class of agents against poten-
tial risks. While a recently conducted case–control study
found an association between 10 years or more of calcium
channel blocker use and invasive breast cancer [1], our
prospective study of 50,757 women with a family history
of breast cancer yielded no evidence of increased risk.
There is no strong biological rationale for increased
cancer risk resulting from long-term use of calcium
channel blockers. It has been hypothesized that use of
calcium channel blockers may inhibit intracellular cal-
cium channels involved in signaling and coordinating
cell apoptosis [19]. Changes in intracellular calcium con-
centrations are involved in response pathways to various
apoptotic stimuli in many cell types, as well as in the
process of DNA fragmentation during apoptosis. Inter-
ference with the apoptotic process could potentially
allow tumor growth [20–22]. However, in-vivo studies
Table 3 Hazard ratios for invasive ductal carcinomas, invasive











Never used Reference Reference Reference
Former user 1.05 (0.59–1.86) 1.68 (0.41–6.85) 0.98 (0.41–2.38)
Current user
(<5 years)
0.66 (0.45–0.97) 2.26 (1.12–4.55) 0.78 (0.46–1.35)
(5–10 years) 1.05 (0.66–1.66) 1.13 (0.28–4.61) 1.28 (0.68–2.41)
(10+ years) 0.80 (0.45–1.42) 0.69 (0.10–4.99) 0.80 (0.33–1.94)
All antihypertensives
Never used Reference Reference Reference
Former user 1.03 (0.69–1.53) 0.30 (0.04–2.16) 1.15 (0.66–2.01)
Current user
(<5 years)
0.90 (0.74–1.08) 0.88 (0.51–1.50) 1.06 (0.82–1.39)
(5–10 years) 0.97 (0.77–1.22) 1.21 (0.65–2.24) 0.87 (0.60–1.26)
(10+ years) 0.94 (0.74–1.19) 0.57 (0.24–1.34) 0.88 (0.60–1.28)
Data presented as hazard ratio (95 % confidence interval)
Hazard ratios were calculated using Cox proportional hazards regression with
age as the time scale and adjusted for race/ethnicity, categorized body mass
index, parity, age at menarche, menopause status, statin use, smoking status,
hormone therapy use, and reported hours of physical activity per week
Table 4 Hazard ratios of incident breast cancer by strata of
calcium channel blocker use in long-term antihypertensive users
Calcium channel blockers Limited to women
currently using an
antihypertensive
drug for 5 years




drug for 10 years
or more (N = 3879)
Never used Reference Reference
Former user 0.87 (0.36–2.11) 0.80 (0.20–3.24)
Current user (<5 years) 1.06 (0.71–1.58) 1.09 (0.60–1.99)
(5–10 years) 1.14 (0.81–1.61) 1.15 (0.58–2.29)
(10+ years) 0.89 (0.58–1.36) 0.89 (0.57–1.40)
Data presented as breast cancer hazard ratio (95 % confidence interval)
Hazard ratios of incident breast cancer by strata of calcium channel blocker
use in long-term antihypertensive users when the analytic population is
limited to women who have been using an antihypertensive drug for at least
5 years (N = 8058) or at least 10 years (N = 3879) at baseline. Hazard ratios
were calculated using Cox proportional hazards regression with age as the
time scale and adjusted for race/ethnicity, categorized body mass index, parity,
age at menarche, menopause status, statin use, smoking status, hormone
therapy use, and reported hours of physical activity per week
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and animal models have shown inconsistent relationships
between calcium channel blocking drugs and apoptosis;
treatment with the drugs promotes apoptosis in some
cancerous and noncancerous cell types and reduces apop-
tosis in others [23–29]. In fact, calcium channel blocking
drugs appear to have antitumorigenic properties in some
situations [30–33]. This lack of convincing biological evi-
dence is consistent with the observed lack of association
between calcium channel blocker use and breast cancer
risk in this study.
The study by Li et al. [1] was a large case–control
study of women comprising 880 invasive ductal carcin-
oma cases, 1027 invasive lobular carcinoma cases, and
856 controls. Their exposure surveys collected detailed
information on the use and duration of various classes
of antihypertensive drugs. Detailed information on dur-
ation of use for subclasses of antihypertensive drugs has
not been available in most contemporary studies of
breast cancer, so this finding was particularly concerning.
However, retrospectively collected exposure information
may be subject to recall bias between women with cancer
and the population-based controls. The Sister Study’s
medication questionnaire method collected very similar
information; however, the questionnaires in the Sister
Study were administered prospectively, before any diagno-
sis of breast cancer occurred. Additionally, the observed
risk increases in the study be Li et al. were based on a total
of 70 women reporting 10 years or more of calcium chan-
nel blockers use (N = 12 controls, 27 invasive ductal car-
cinoma, and 31 invasive lobular carcinoma). The small
number of long-term users of the calcium channel blocker
subclass resulted in wide CI estimates.
Our observed lack of association between calcium
channel blocker use and breast cancer risk in this Sister
Study is consistent with the results of recently published
analyses from the Nurse’s Health Study [12] and the
Swedish National Board of Health and Welfare [13].
Both of these studies used prospectively collected data
from large cohorts, either from questionnaires or from
Swedish Prescription Drug registries which track drug
dispensations. Although the Swedish study did not have
sufficient numbers of users with 10 years or more of cal-
cium channel blocker use to evaluate risk for those
women, neither study found any increased risk of breast
cancer development with ever having used calcium
channel blockers. We are able to extend these findings
to women who are known to be at a higher risk by virtue
of having an affected sister, providing additional weight
to the argument that calcium channel blockers do not
increase breast cancer risk.
Although a small number of women may change med-
ications after enrollment questionnaire assessment, such
changes would not be expected to bias risk estimates
which are based solely on medication use up to the time
of enrollment. This analysis is also limited by a relatively
short mean follow-up time of 5.3 years.
While there was no association between calcium chan-
nel blocker use and development of breast cancer, we
did observe that calcium channel blocker use, and use of
antihypertensives in general, is associated with several
breast cancer risk factors. Women who used calcium
channel blockers in our study were more likely to have a
history of smoking, to be overweight, to be postmeno-
pausal, and to have used hormone replacement therapy.
These associations might help to explain the inconsist-
encies observed in past studies of breast cancer risk and
antihypertensive drug use. Incomplete adjustment for
the differences in risk profiles between calcium channel
blocker users and nonusers might produce associations
between calcium channel blocker use and breast cancer,
particularly in smaller studies.
Conclusions
Reports of potential excess risk due to antihypertensive
drugs are likely to be of particular concern for women
with increased breast cancer risk from genetic or other
factors. Such concern might lead to less effective treat-
ment for hypertension. Our findings in women with a
family history of breast cancer and the findings from other
recent prospective studies indicate that calcium channel
blocking drugs can be used for long-term hypertension
treatment without concern about increases in breast
cancer risk.
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